Erratum: Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose? (European Journal of Clinical Pharmacology (2004) 60 (221-224) DOI: org/10.1007/s00228-004-0748-x);Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?

European Journal of Clinical Pharmacology

Volumn 60, Issue 3, 2004, Pages 221-224

  Bateman, D N ^a   Chick, J ^b   Good, A M ^a   Kely, C A ^a   Masterton, G ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b ROYAL EDINBURGH HOSPITAL   (United Kingdom)

Author keywords

Antidepressant; Selective serotonin re uptake inhibitors; Self harm

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; ARTICLE; AUTOMUTILATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG OVERDOSE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HOSPITAL PATIENT; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 2942618834     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0898-5     Document Type: Erratum

References (15)

1. Teicher MH, Glod C, Cole JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatr 147:207-210
2. Donovan S, Clayton A, Beeharry M, Jones S, Kirk S, Waters K, Gardner D, Faulding J, Madely R (2000) Deliberate self-harm and antidepressant drugs. Br J Psychiatr 177:551-556
3. Townsend E, Hawton K, Harriss L, Bale E, Bond A (2001) Substances used in deliberate self-poisoning 19085-1997: trends and associations with age, gender, repetition and suicide intent. Soc Psychiatry Psychiatr Epidemiol 36:228-234
4. Bateman DN, Bain M, Gorman D, Murphy D (2003) Changes in paracetamol, antidepressants and opioid poisoning in Scotland during the 1990s. Quart J Med 96:125-132
5. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P (2003) Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 326:1008-1011
6. Khan A, Khan S, Kolts R, Brown WA (2003) Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports. Am J Psychiatr 160:790-792
7. Healy D (2003) Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72:71-79
8. Duff G (2003) Safety of Seroxat (paroxetine) in children and adolescents under 18 years - contraindication in the treatment of depressive illness.http://MRHA.gov.uk [10 June 2003]
9. Anonymous (2003) Paroxetine. Summary of product characteristics.http:// www.gsk.com [Accessed 2003]
10. Mehta DK (2003) British National Formulary 45. March 2003, Pharmaceutical Press, UK
11. Bateman DN, Good AM, Kelly CA, Laing WJ (2002) Web based information on clinical toxicology for the United Kingdom: uptake and utilization of TOXBASE in 2000. Br J Clin Pharmacol 54:3-9
12. Bateman DN, Good AM, Afshari R, Kelly CA (2003) Effects of license change on prescribing and poisons inquiries for antipsychotic agents in England and Scotland. Br J Clin Pharmacol 55:596-603
13. Buckley NA, McManus PR (2002) Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325:1332-1333
14. Cassidy S, Henry J (1987) Fatal toxicity of antidepressant drugs in overdose. BMJ 295:1021-1024
15. Kelly CA, Dhaun N, Laing WJ, Strachan FE, Good AM, Bateman DN (2004) Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Tox 42:67-71